Literature DB >> 26456567

An epidemiological serosurvey of hepatitis B virus shows evidence of declining prevalence due to hepatitis B vaccination in central China.

Guo Yonghao1, Xu Jin2, Li Jun2, Dong Pumei2, Ye Ying2, Feng Xiuhong2, Zhang Yanyang2, Guo Wanshen2.   

Abstract

OBJECTIVE: The hepatitis B vaccine was first introduced into the routine immunization program in Henan Province, China in 1992. In 2012, a survey was conducted to evaluate the protective effects of hepatitis B vaccination for the populations born during the preceding 15 years.
METHODS: A multistage stratified random cluster sampling method was used to collect samples. The participants were interviewed and relevant information was obtained for the population aged 1 to 14 years using a standardized questionnaire; a 2- or 3-ml serum sample was taken from each participant to measure hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc). Association and logistic regression analyses were conducted to determine relationships between these parameters.
RESULTS: A total of 13,207 residents aged 1 to 14 years residing in 60 villages or communities in Henan, China were surveyed and had their blood collected. Serological analysis revealed that the HBsAg and anti-HBc prevalences were 0.8% and 2.6%, respectively. The HBsAg prevalence among children under 5 years of age was 0.5%, showing a decline of 96% compared to the average national HBsAg prevalence in 1992. Children had a higher likelihood of HBsAg positivity if they had an HBsAg-positive family member (odds ratio (OR) 4.26), no history of vaccination (OR 2.06), were born in a smaller township hospital or at home (OR 1.61), were aged 10-14 years (OR 2.07), or were living in a rural area (OR 2.01).
CONCLUSIONS: The HBsAg prevalence rate in persons under 15 years of age has dropped significantly in Henan Province after two decades of vaccination. Thus millions of chronic HBV infections have been prevented.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Henan; Hepatitis B; Immunization; Serosurvey

Mesh:

Substances:

Year:  2015        PMID: 26456567     DOI: 10.1016/j.ijid.2015.10.002

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  14 in total

1.  Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA.

Authors:  Eliza W Beal; Dmitry Tumin; Ali Kabir; Dimitrios Moris; Xu-Feng Zhang; Jeffery Chakedis; Kenneth Washburn; Sylvester Black; Carl M Schmidt; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-03       Impact factor: 3.352

2.  Association of diabetes mellitus with hepatitis B and hepatitis C virus infection: evidence from an epidemiological study.

Authors:  Yujia Liu; Shangyuan Ye; Xianchao Xiao; Tong Zhou; Shuo Yang; Gang Wang; Chenglin Sun; Bo Zhang; Guixia Wang
Journal:  Infect Drug Resist       Date:  2019-09-12       Impact factor: 4.003

3.  Integrating nested PCR with high-throughput sequencing to characterize mutations of HBV genome in low viral load samples.

Authors:  Xianjun Wang; Lihui Xu; Yueming Chen; Anbing Liu; Liqian Wang; Peisong Xu; Yunhui Liu; Lei Li; Fei Meng
Journal:  Medicine (Baltimore)       Date:  2017-07       Impact factor: 1.889

Review 4.  The Effect of Hepatosteatosis on Response to Antiviral Treatment in Patients with Chronic Hepatitis B: A Meta-Analysis.

Authors:  Yongfen Zhu; Qiao Yang; Fangfang Lv; Yunsong Yu
Journal:  Gastroenterol Res Pract       Date:  2017-03-21       Impact factor: 2.260

5.  Changes in hepatitis B virus antibody titers over time among children: a single center study from 2012 to 2015 in an urban of South Korea.

Authors:  Kyeong Hun Lee; Kyu Seok Shim; In Seok Lim; Soo Ahn Chae; Sin Weon Yun; Na Mi Lee; Young Bae Choi; Dae Yong Yi
Journal:  BMC Pediatr       Date:  2017-07-14       Impact factor: 2.125

6.  Analysis of epidemiological serosurvey of hepatitis B virus among people under 29 years of age in Jiangsu Province, China.

Authors:  Xiang Sun; Yuanyuan Zhu; Fenyang Tang; Xiuying Deng; Zhiguo Wang; Yuanbao Liu
Journal:  Hum Vaccin Immunother       Date:  2021-06-07       Impact factor: 4.526

7.  Impact of age on the diagnostic performances and cut-offs of APRI and FIB-4 for significant fibrosis and cirrhosis in chronic hepatitis B.

Authors:  Qiang Li; Chuan Lu; Weixia Li; Yuxian Huang; Liang Chen
Journal:  Oncotarget       Date:  2017-07-11

8.  Diagnostic accuracy of liver stiffness measurement in chronic hepatitis B patients with normal or mildly elevated alanine transaminase levels.

Authors:  Qiang Li; Liang Chen; Yu Zhou
Journal:  Sci Rep       Date:  2018-03-27       Impact factor: 4.379

9.  Taurocholic acid is an active promoting factor, not just a biomarker of progression of liver cirrhosis: evidence from a human metabolomic study and in vitro experiments.

Authors:  Zhimin Liu; Zhifeng Zhang; Mei Huang; Xiaoping Sun; Bojia Liu; Qiyang Guo; Qingshan Chang; Zhijun Duan
Journal:  BMC Gastroenterol       Date:  2018-07-11       Impact factor: 3.067

10.  Hepatitis B knowledge among key stakeholders in Haimen City, China: Implications for addressing chronic HBV infection.

Authors:  Chari Cohen; Alison A Evans; Peixin Huang; W Thomas London; Joan M Block; Gang Chen
Journal:  Hepatol Med Policy       Date:  2016-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.